ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0278

Clinical Outcomes in Patients with Anemia in CKD Using Linked US Claims and Electronic Health Records

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Wittbrodt, Eric T., AstraZeneca, Wilmington, Delaware, United States
  • James, Glen, AstraZeneca, Cambridge, United Kingdom
  • Kumar, Supriya R., AstraZeneca, Gaithersburg, Maryland, United States
  • Garcia Sanchez, Juan Jose, AstraZeneca, Cambridge, United Kingdom
  • Chen, Hungta (tony), AstraZeneca, Gaithersburg, Maryland, United States
  • Sloand, James A., AstraZeneca, Gaithersburg, Maryland, United States
  • Kalantar-Zadeh, Kamyar, University of California - Irvine, Irvine, California, United States
Background

Anemia is common in pts with CKD, yet contemporary outcome data to understand the long-term clinical burden are scarce. This analysis describes selected cardiovascular and renal outcomes in non-dialysis CKD pts with and without anemia at baseline (BL) in US real-world practice.

Methods

This retrospective observational study evaluated the integrated Limited Claims and Electronic Health Record data (IBM Health, Armonk, NY). Pts were aged ≥18 y with ≥2 eGFR measures <60 mL/min/1.73 m2 ≥90 days apart. Anemia was defined as the presence of any observed Hb <10 g/dL within ± 6 months of confirmatory eGFR (anemia BL period). In addition, the BL period for disease history was defined as the start of pt data + 6 months, and for lab measures and medications was defined as date of the second confirmatory eGFR + 6 months. Pts with active bleeding, chronic dialysis, and iron deficiency anemia were excluded. BL pt characteristics and clinical outcomes during follow-up were analyzed for the period from Jan 1, 2012 to Sep 30, 2017. Descriptive data were summarized; no inferential statistics were performed.

Results

Of the total study cohort (N=22,720), 23% (n=5283) had BL Hb <10 g/dL. The following results are for pts with and without anemia at BL, respectively. Females accounted for 60% and 57% and mean ages (± SD) were 70 (14) and 71 (12) y. Proportions by BL CKD stage were: 3a, 50% and 68%; 3b, 27% and 24%; 4, 15% and 7%; 5, 9% and 1%. Median follow-up times were 2.9 and 3.8 y. Acute coronary syndrome (ACS) events during follow-up occurred in 2.2% of pts with BL anemia and 2.3% of pts without BL anemia, heart failure hospitalizations (hHF) occurred in 5.9% and 3.7%, and stroke hospitalizations and emergency visits (S) occurred in 2.8% and 3.0% of pts. Incidence rates rates/100 pt-y were 0.8 and 0.7 for ACS, 1.6 and 0.8 for hHF, respectively, and 0.7 in both groups for S. ESRD occurred in 4% and 1%, 40% eGFR decrease in 44% and 25%, and CKD stage progression in 67% and 59% of pts. Median change in eGFR slope was –0.6 and –0.3 mL/min/1.73 m2.

Conclusion

This analysis highlights worsened outcomes associated with anemia in CKD, particularly hHF and eGFR decline, in pts of a large US cohort.

Funding

  • Commercial Support